연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1350 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Jang, In-Jin | Jang, IJ | 17 | Seoul Natl Univ Hosp, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea | J-2786-2012 | Jang, In-Jin | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Capeding, Maria Z. | Capeding, MZ | 18 | Trop Dis Fdn San Francisco Multipurpose Bldg, Laguna 4000, Philippines | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Roman, Francois | Roman, F | 19 | GlaxoSmithKline Vaccines, Wavre, Belgium | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Breuer, Thomas | Breuer, T | 20 | GlaxoSmithKline Vaccines, Wavre, Belgium | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Wysocki, Piotr | Wysocki, P | 21 | GlaxoSmithKline Vaccines, Warsaw, Poland | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Carter, Lauren | Carter, L | 22 | Univ Washington, Dept Biochem, Seattle, WA USA | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Carter, Lauren | Carter, L | 22 | Univ Washington, Inst Prot Design, Seattle, WA USA | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Sahastrabuddhe, Sushant | Sahastrabuddhe, S | 23 | Int Vaccine Inst, Seoul, South Korea | 0000-0003-1751-3905 | SAHASTRABUDDHE, SUSHANT | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Song, Manki | Song, MK | 24 | Int Vaccine Inst, Seoul, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | D'Cor, Naveena | D'Cor, N | 25 | Int Vaccine Inst, Seoul, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Kim, Hun | Kim, H | 26 | SK Biosci Co Ltd, Res & Dev, Seongnam, South Korea | B-9921-2013 | Kim, Tae | heejinmd@korea.ac.kr; | |||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Ryu, Ji Hwa | Ryu, JH | 27 | SK Biosci Co Ltd, Res & Dev, Seongnam, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Lee, Su Jeen | Lee, SJ | 28 | SK Biosci Co Ltd, Res & Dev, Seongnam, South Korea | heejinmd@korea.ac.kr; | |||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Park, Yong Wook | Park, YW | 29 | heejinmd@korea.ac.kr; | ||||||
| Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | Cheng, Hee Jin | Cheng, HJ | 30 | 교신저자 | Korea Univ, Korea Univ Guro Hosp, Dept Internal Med, Div Infect Dis,Coll Med, 148 Gurodong Ro, Seoul 08308, South Korea | 0000-0002-2532-1463 | Cheong, Hee Jin | heejinmd@korea.ac.kr; |
페이지 이동: